Filing Overview
Xeris Biopharma Holdings, Inc. filed a Form 8-K on January 4, 2024, under Item 2.02 and Item 9.01. The filing furnishes a press release announcing certain preliminary results for the year ended December 31, 2023.
Financial Results and Liquidity
The filing text provided does not include the attached Exhibit 99.1 press release or any specific financial results. Revenue, profit or loss, cash flow, margins, debt, liquidity, and other key metrics are therefore not clearly provided.
Changes, Outlook, and Risks
The filing text does not provide sufficient information to assess changes versus the prior comparable period, management guidance, outlook, risks, contingencies, or unusual items. Because the results were preliminary, the reported figures may be subject to change in subsequent filings.
Important Facts to Verify
- Obtain and review Exhibit 99.1 for the preliminary 2023 results and management commentary.
- Verify final audited 2023 results against the company’s subsequent annual report or other financial filing.
- Confirm revenue, profitability, cash flow, liquidity, debt, and any guidance or non-GAAP measures disclosed in the press release.